HYPOTENSIVE METHODS AND COMPOSITIONS UTILIZING HEXAHYDROBENZO{8 b{9 {0 QUINOLIZINES

ABSTRACT

A hypotensive effect is achieved through the use of hexahydrobenzo(b)quinolizines characterized by the presence of at least 2 hydroxy or 2 alkoxy groups in the 7, 8, 9 and 10 positions. Also disclosed are pharmaceutical compositions utilizing these compounds.

United States Patent [72] Inventors Jeffrey W. 11. Watthey;

Karl J. Doebel, both of Osslnlng, N.Y. 862,092

Mar. 17, 1969 Nov. 16, 1971 Geigy Chemical Corporation Ardsley, N.Y.

Original application Nov. 7, 1967, Ser. No. 681,078, now Patent No. 3,484,443, dated Dec. 16, 1969. Divided and this application Mar. 17, 1969, Ser. No. 862,092

[21 1 App]. No. [22] Filed [45] Patented [73] Assignee [54] HYPOTENSIVE METHODS AND COMPOSITIONS UTILIZING HEXAHYDROBENZO[b] OTHER REFERENCES Kupchan, .l., Org. Chem., Vol. 31, pp 1713- 16 1966).

Primary Examiner-Jerome D Goldberg Attorneys- Karl F. Jorda, Bruce M, Collins and Martin J.

Spellman, .lr.

ABSTRACT: A hypotensive effect is achieved through the use of hexahydrobenzo [b] quinolizines characterized by the presence of at least 2 hydroxy or 2 alkoxy groups in the7, 8, 9 and 10 positions. Also disclosed are pharmaceutical compositions utilizing these compounds.

HYPOTENSIVE METHODS AND COMPOSITIONS UTILIZING I-IEXAHYDROBENZO[b]QUINOLlZINES CROSS-REFERENCE The compounds of the invention may be used in warm- This is a divisional of Ser. No. 681,078 filed Nov. 7, 1967, 5 l oded animals. particularly mammals, as medicaments in now U.S. Pat. No. 3,484,443. the form of pharmaceutical compositions containing the compounds in admixture or conjunction with a pharmaceutical or- T E DE R I ganic or inorganic, solid or liquid carrier for oral, rectal, or The present invention pertains to hyposensitive methods 23;??? i i iz sgg gi i 33 23 las s"; and compositions utilizing a compound which may be characlk p e y terized by the following formula 1: to

The preferred route of administration is the oral route. I Suitable compositions include, without limitation, tablets, 1 2 capsules, powders, solutions, suspensions, sustained release O l formulations and the like. R: 8 7 To produce dosage units for peroral application, the comy positions of this invention may be combined, e.g. with solid h i R1 pharmaceutically acceptable pulverulent carriers such as lac- R, is hydrogen, lower alkyl, hydroxy, lower alkyl or lower sacchafose, sorbitol, mannitol; starches Such as Potato lk l starch, corn starch or amylopectin, also laminaria powder or R i h dm h d l alkoxy or lower alkanwlox. citrus pulp powder, cellulose derivatives or gelatin, also lubricants such as magnesium or clacium stearate or polyethylene R is hydrogen, hydroxy, lower alkoxy, or lower alkanoylox- B y (Carbowaxes) of suitable mbleculal' weights y be d added, to form tablets or press coated tablets. The latter are R i hydrogen, h d lower alkoxy, lower alkanwlox. coated for example, with concentrated sugar solutions which y, can contain e.g. gum arabic, talcum and/or titanium dioxide, with the proviso that if R is hydrogen, R must be hydroxy or they are coated lacquer dissolved in easily volatile orlower aloxy or alkanoyloxy, and pharrnaceutically acceptable gamc solvents or a mixture of organic solvents. Dyestufls can acid addition salts th f be added to these coatings, for example, to distinguish The term pharmaceutically acceptable acid addition n between different contents of active substances. when used herein and in the appended claims signifies those Hard gelatin capsules contain, for example, granulates of derived from organic and inorganic acids. illustrative of the the instant composition with solid pulverulent carriers such as acids which form pharrnaceutically acceptable addition salts e.g. lactose, saccharose, sorbitol, mannitol and further with the instantly claimed compounds are, for exam le, starches such as potato starch, corn starch or amylopectin, hydrochloric, hydrobromic sulfuric, phosphoric, methanesulcellulose derivatives or gelatin, as well as magnesium stearate fonic, acetic, lactic, succinic, malic, aconitic, phthalic, tartaror stearic acid. P and like- Suppositories containing a compound of the present inven- The compounds utilized in the methods and Compositions of tion are readily obtained by techniques well known to those the Present invention are P P according methods skilled in the art of compounding dosage fonns. A compound described in U.S. Pat. N0. 3,484,443, the diSCIOSUf Of which of the present invention is dispersed in a carrier such as cocoa is hereby incorporated y butter and the suppositories formed in the usual way.

The compounds utilized in the method and composition of I the present invention ie com unds of the above-described what's clalmedl-S' a] f la and h :3 km t [arable Cid addi l. Apharmaceutical hypotensivc composition comprising in e r p y l g o a dosage unit form a pharmaceutical carrier and a hypotensively Possess valuable pliarmacologlcal and therapeyuc efiective amount of a compound selected from the group conpmpem.e.s and may used m the .form of pharmafeuncal sisting of (a) a hydroxyhexghydrobenzo(b) quinolizine of the compositions, especially as cardiovascular, particularly formula, hypotensive, and CNS active, particularly CNS stimulating and depressing agents. it is of special interest that the compounds having alkoxy groups in the unsaturated ring are particularly valuable hypotensive agents and especially those wherein R, is hydrogen, lower alkyl, or lower alkoxy, and R,, R,, and R, are hydrogen of lower alkoxy, at least two of R,, R,,, RP R,, and R,, being adjacent lower alkoxy groups, with the proviso that if R, is hydrogen, R is lower alkoxy. /N\/ The toxicity of the compounds of the instant invention is low; for instance, the LD, of 9,10-di-hydroxy-7-isopropyli,3,4,6,l 1,1 ia-hexahydrobenzo(b) quinolizine hydrobromide administered orally to mice is approximately 250 mg./kg. in the case of 9,10-dihydroxy-7-methyl-l,3,4,6,l1,1 1a-hexahydrobenzo (b) quinolizine hydrobromide, no deaths were wherein R, is hydrogen, lower alkyl or hydroxy, and observed when the substance was administered orally to mice each of R,, R,, and R is hydrogen or hydroxy, at least at doses up to [,250 mgJkg. two of R,, R,, R,, and R, being hydroxy, with the The cardiovascular activity was studied .in the intact, proviso that if R, is hydrogen, R, is hydroxy, (b) an alkoxanesthetized cat, as follows: yhexahydrobenzo(b)quinolizine of the formula:

Route,

intra- Blood pressure Duration venous of hypo- Dose, 0r intrn' Control Response tension, Compound administered mg./kgr duodenal (maximum) minutes 8,9-dimethoxy 7-methyi-1,3,4,6,11,11a-hexahydrobenzolblquinoiizine 3 IN. /48 /33 3 1.V. 130/80 /60 15+ 8,9,10-trimethoxy-1,3,4,6,11,l1a-hexahydrobenzolbhuinolizine 10 [.V. 125/80 70/55 17+ 30 1).U. 146/58 l /38 90 9,10-dimcth0xy-7-isopropyl-l,3,4,6,11,1ia-hexahydrobenzo[blquinolizine H 3 IN. /65 80/45 7,10-dimethoxy-1,3,4,6,11,118-hexahydrobenzo[b]quinoiizine 3 I.\'. 150/70 100/55 1 I Blood pressure reading 90 minutes after administration of the substance.

wherein R is hydrogen, methyl or lower alkoxy; and

each of R,,, R and R is hydrogen or lower alkoxy, at

least two of R,, R R and R being adjacent lower alkoxy with the proviso that if R, is hydrogen, R is lower alkoxy, and (c) a pharmaceutically acceptable acid addition salt thereof.

2. A composition according to claim 1 wherein said compound is 8,9-dimethoxy-7-methyl-l,3,4,6,l l,l la-hexahydrobenzo-(b)quinolizine.

3. A composition according to claim 1 wherein said compound is 8,9-dihyroxy-7-methyl-l ,3,4,6,l l,l la-hexahydrobenzo-(b) quinolizine.

4. A composition according to claim 1 wherein said compound is 7,8-dimethoxy-1 ,3,4,6,1 l ,1 la-hexahydrobenzo(b) quinolizine.

5. A composition according to claim 1 wherein said compound is 9,10-dihydroxy-7-methyl-l ,3,4,6,l 1,1 la-hexahydrobenzo( b) quinolizine.

6. A composition according to claim 1 wherein said compound is 7,8dihydroxyl ,3,4,6,l l,l 1a-hexahydrobenzo( b quinolizine.

7. A composition according to claim 1 wherein said compound is 8,9,l-trimethyoxy-l,3,4,6,l l,l la-hexahydrobenzo(b)-quinolizine.

8. A composition according to claim 1 wherein said compound is 8,9,10-tirhydroxy-l .3,4,6,l l,l lahexahydrobenzo(b)-quinolizine.

9. A composition according to claim 1 wherein said compound is 9, 0dimethoxy-7-isopropyll ,3,4,6,l l,l la-hexahydrobenzo(b)quinolizine.

10. A composition according to claim 1 wherein said compound is 9, l 0-dihydroxy-7-isopropyll ,3,4,6,l I ,1 la-hexahydrobenzo(b) quinolizine.

11. A composition according to claim 1 wherein said compound is 7,10-dihydroxy-l ,3,4,6, 1 1,1 l a-hexahydrobenzo(b)- quinolizine.

12. The method of producing a hypotensive effect in a mammal which comprises administering thereto a hypotensively effective amount of a compound selected from the group consisting of (a) a hydroxyhexahydrobenzo(b) quinolizine of the fonnula:

wherein R, is hydrogen, lower alkyl or hydroxy and each of R R and R is hydrogen or hydroxy, at least two of R,, R R and R being hydroxy, with the proviso that if R, is hydrogen. R is hydroxy, (b) an alkoxyhexahydrobenzo( b) quinolizine of the formula:

wherein R, is hydrogen, methyl or lower alkoxy; and

each of R R and R is hydrogen or lower alkoxy, at least two of R,, R R and R being adjacent lower alkoxy with the proviso that if R, is hydrogen, R, is lower alkoxy, and (c) a phannaceutically acceptable acid addition salt thereof. 

2. A composition according to claim 1 wherein said compound is 8,9-dimethoxy-7-methyl-1,3,4,6,11,11a-hexahydrobenzo-(b)quinolizine.
 3. A composition according to claim 1 wherein said compound is 8,9-dihydroxy-7-methyl-1,3,4,6,11,11a-hexahydrobenzo-(b) quinolizine.
 4. A composition according to claim 1 wherein said compound is 7,8-dimethoxy-1,3,4,6,11,11a-hexahydrobenzo(b) quinolizine.
 5. A composition according to claIm 1 wherein said compound is 9,10-dihydroxy-7-methyl-1,3,4,6,11,11a-hexahydrobenzo(b) quinolizine.
 6. A composition according to claim 1 wherein said compound is 7,8-dihydroxy-1,3,4,6,11,11a-hexahydrobenzo(b)-quinolizine.
 7. A composition according to claim 1 wherein said compound is 8,9,10-trimethyoxy-1,3,4,6,11,11a-hexahydrobenzo(b)-quinolizine.
 8. A composition according to claim 1 wherein said compound is 8,9,10-trihydroxy-1,3,4,6,11,11a-hexahydrobenzo(b)-quinolizine.
 9. A composition according to claim 1 wherein said compound is 9,10-dimethoxy-7-isopropyl-1,3,4,6,11,11a-hexahydrobenzo(b)quinolizine.
 10. A composition according to claim 1 wherein said compound is 9,10-dihydroxy-7-isopropyl-1,3,4,6,11,11a-hexahydrobenzo(b) quinolizine.
 11. A composition according to claim 1 wherein said compound is 7,10-dihydroxy-1,3,4,6,11,11 a-hexahydrobenzo(b)-quinolizine.
 12. The method of producing a hypotensive effect in a mammal which comprises administering thereto a hypotensively effective amount of a compound selected from the group consisting of (a) a hydroxyhexahydrobenzo(b) quinolizine of the formula: 